IL2 and neuroblastoma: It is used in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2), and 13-cis-retinoic acid (RA) for the treatment of high-risk NB patients who achieve at least a partial response to prior first-line therapy [272].